Guggenheim assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note published on Monday, The Fly reports. The brokerage issued a buy rating and a $5.00 price objective on the stock.
A number of other research firms have also recently issued reports on TXMD. BidaskClub cut TherapeuticsMD from a sell rating to a strong sell rating in a research note on Thursday, November 28th. HC Wainwright reaffirmed a buy rating and issued a $7.00 price target on shares of TherapeuticsMD in a research note on Tuesday, October 29th. Zacks Investment Research raised shares of TherapeuticsMD from a sell rating to a hold rating in a research note on Saturday, October 19th. ValuEngine cut shares of TherapeuticsMD from a buy rating to a hold rating in a report on Friday, November 1st. Finally, Noble Financial reissued a buy rating and set a $13.00 price objective on shares of TherapeuticsMD in a research report on Friday, September 27th. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $9.60.
NASDAQ:TXMD opened at $2.42 on Monday. TherapeuticsMD has a 1 year low of $1.82 and a 1 year high of $6.09. The stock has a 50-day moving average price of $2.95 and a two-hundred day moving average price of $2.93. The stock has a market cap of $656.25 million, a price-to-earnings ratio of -4.10 and a beta of 1.66. The company has a current ratio of 2.85, a quick ratio of 2.69 and a debt-to-equity ratio of 24.29.
In other TherapeuticsMD news, major shareholder Group L. P. Column purchased 4,387 shares of the firm’s stock in a transaction dated Wednesday, October 23rd. The stock was bought at an average cost of $12.66 per share, with a total value of $55,539.42. Also, Director Brian Bernick purchased 36,000 shares of the firm’s stock in a transaction dated Friday, October 25th. The shares were acquired at an average cost of $2.75 per share, with a total value of $99,000.00. Following the completion of the purchase, the director now directly owns 98,000 shares in the company, valued at $269,500. The disclosure for this purchase can be found here. Insiders acquired a total of 112,387 shares of company stock worth $352,539 in the last 90 days. Company insiders own 18.91% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Menta Capital LLC grew its position in TherapeuticsMD by 184.5% in the second quarter. Menta Capital LLC now owns 33,000 shares of the company’s stock valued at $86,000 after purchasing an additional 21,400 shares in the last quarter. Highland Private Wealth Management bought a new stake in TherapeuticsMD during the 2nd quarter worth about $28,000. Cetera Advisors LLC boosted its stake in shares of TherapeuticsMD by 11.1% during the 3rd quarter. Cetera Advisors LLC now owns 104,975 shares of the company’s stock worth $384,000 after buying an additional 10,450 shares during the last quarter. Carlson Capital L P boosted its stake in shares of TherapeuticsMD by 928.2% during the 2nd quarter. Carlson Capital L P now owns 785,000 shares of the company’s stock worth $2,041,000 after buying an additional 708,650 shares during the last quarter. Finally, H D Vest Advisory Services acquired a new position in shares of TherapeuticsMD during the 2nd quarter worth about $34,000. Institutional investors and hedge funds own 63.63% of the company’s stock.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.
Featured Story: Cost of Capital Explained
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.
